

Patent Selections:

The patents annotated in this section have been selected from various patent databases. These recent patents are relevant to the articles published in this journal issue, categorized by therapeutic areas/targets & therapeutic agents related to endocrine, metabolic and immune drug discovery.

HOMEOSTASIS & INFLAMMATION

1. Henry, M. O., Lynn, W. S. Modulation of cell fates and activities by phthalazinediones. *US7691819 (2010)*.
2. Chimienti, F., Hogg, R., Huber, M., Bertrand, D., Hohl, D. Use of SLURP-1 for treating diseases related to acetylcholine receptor dysfunction. *US7691808 (2010)*.
3. Ekhardt, P. F., Van Der Saag, H., Possemiers, S., Van Den Abbeele, P., Van De Wiele, T. Arabinoxylans for modulating the barrier function of the intestinal surface. *WO2010020639 (2010)*.

HOMEOSTASIS & SERUM AMYLOID A

1. Bielicki, J. K., Natarajan, P. Helical synthetic peptides that stimulate cellular cholesterol efflux. *US7691965 (2010)*.
2. Clark, A. F., Wang, W.-H., McNatt, L. G. Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents. *US20100063052 (2010)*.
3. Gazit, E. Peptides directed for diagnosis and treatment of amyloid-associated diseases. *US20100022459 (2010)*.
4. Xu, W., Kindsvogel, W., Hughes, S. D., Chandrasekher, Y. A. Anti-IL-TIF antibodies. *US7674461 (2010)*.
5. Sprecher, C. A., Kuijper, J. L., Dasovich, M. M., Grant, F. J., Whitmore, T. E., Hammond, A. K., Novak, J. E., Gross, J. A., Dillon, S. R. Cytokine receptor ZCYTOR17 multimers. *US20100055101 (2010)*.
6. Jaspers, S. R., Rixon, M. W., Dillon, S. R., Ramsdell, F. J., Krejsa, C. M., Yi, E. C. Anti-human IL-21 monoclonal antibodies. *US20100041873 (2010)*.

CD4 REGULATORY T CELLS & ALLOANTIGEN SPECIFIC

1. Stepkowski, S. M. Nitric oxide increases switching of T cells into T regulatory cells. *US20100003271 (2010)*.
2. Banchereau, J. F., Berard, F., Blanco, P., Neidhart-Berard, E.-M., Nouri-Shirazi, M., Palucka, A. K. Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses. *EP2151245 (2010)*.

3. Hasumi, K., Imaizumi, A., Iwama, M., Goto, M. Adoptive immune cells for tumor vaccines. *US7655393 (2010)*.
4. Levy, G. Use of Soluble FGL2 as an immunosuppressant. *US20100048486 (2010)*.
5. Har-Noy, M. Th1 vaccination priming for active immunotherapy. *US20100086561 (2010)*.

INBORN ERRORS & GENE THERAPY

1. Tang, J. N., Ghosh, A. K. Inhibitors of memapsin 2 and use thereof. *US7678760 (2010)*.
2. Franks, S., Hillier, S. Gonadotrophins in the treatment anovulatory women. *US7695721 (2010)*.

EMZYEMS & METABOLISM

1. Lockwood, S. F., O'Malley, S., Jackson, H., Nadolski, G. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation. *US7691901 (2010)*.

CELL MEMBRANE & PHOTOOXIDATION

1. Bourke, F.A. Jr., Vo, D.T. Advanced methods and systems for treating cell proliferation disorders. *WO2010009106 (2010)*.
2. Umeda, N., Mochizuki, N., Uchida, S., Ikeyama, S. Diamine derivative, production process therefor and antioxidant. *US7652155 (2010)*.

HYPERPARATHYROIDISM & CALCIMIMETICS

1. Zhu, F.-G., Kandimalla, E., Agrawal, S. Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto. *WO2010042543(2010)*.
2. Hwang, J.-K. Novel use of panduratin derivative or *Boesenbergia pandurata* extract. *WO2010041908 (2010)*.

HYPERLIPIDEMIA & FIBRATES

1. Luskey, K. L., Luo, J. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia. *US20100093855 (2010)*.
2. Takizawa, T., Inoue, N., Miyosawa, K. Prophylactic and/or therapeutic agent for hyperlipidemia. *US20100069433 (2010)*.
3. Meerpoel, L., Viellevoye, M. Lipid lowering biphenylcarboxamides. *US7642378 (2010)*.

PRIMARY HYPERPARATHYROIDISM & PARATHYROIDECTOMY

1. Lu, C., Sheppard, K.-A., Porter, J., Bauer, A. Use of TGF-beta antagonists in treatment of parathyroid-related disorders. *US20100003256 (2010)*.
2. Zahradnik, R. J., Lavigne, J. R. Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH). 1-84. *US7670805 (2010)*.

DENDRITIC CELL & CANCER VACCINE

1. Hasumi, K. Dendritic cell tumor injection therapy and related vaccine. *EP2091334 (2010)*.
2. MacDonald, G. H., Martin, B. K., Johnston, R. E., Ting, J. P.-Y. Cancer vaccine comprising alphavirus replicon particles. *EP1069908 (2010)*.
3. Wang, P., Li, S. Microsome vaccine. *EP1648498 (2010)*.
4. Ahmed, R., Larsen, C. P., Araki, K. Use of mTOR inhibitors to enhance T cell immune responses. *WO2010017317 (2010)*.
5. Lanar, D., Burkhard, P. Malaria vaccine of self-assembling polypeptide nanoparticles. *WO2010002818 (2010)*.
6. Dengjel, J. Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules. *EP1806358 (2010)*.
7. Adema, G. J., Meyaard, L., Gorman, D. M., Mcclanahan, T. K., Zurawski, S. M., Zurawski, G., Lanier, L. L., Phillips, J. H. Isolated mammalian monocyte cell genes. *EP0948623 (2010)*.
8. Rhee, C.-S., Sen, M., Wu, C., Leoni, L. M., Corr, M., Carson, D. A. Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas. *US7682607 (2010)*.

AUTOIMMUNITY & CELL CULTURE

1. McSwiggen, J., Beigelman, L. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA). *US7683165 (2010)*.
2. Perron, H., Beseme, F., Bedin, F., Paranhos-Baccala, G., Komurian-Pradel, F., Jolivet-Reynaud, C., Mandrand, B., Garson, J. A., Tuke, P. W. Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes. *US7674888 (2010)*.
3. Merckenschlager, M. M. Use of PI3K M-TOR and Akt inhibitors to induce FOXP3 expression and generate regulatory T Cells. *US20100034786 (2010)*.
4. Baier, G., Hermann-Kleiter, N. Antagonists of NR2F6 for augmenting the immune response. *WO2010004051 (2010)*.

HDL CHOLESTEROL & HYPERLIPIDEMIA

1. Kuo, G.-H., Zhang, Y., Shen, L., Lu, S., Demarest, K.T., Pelton, P. Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol. *US7678786 (2010)*.
2. Starke, I., Dahlstrom, M.U.J., Blomberg, D. Benzothiazepine derivatives for the treatment of hyperlipidemia. *EP1427713 (2010)*.
3. Kuroita, T., Igawa, H., Sakamoto, H., Asano, K., Sasaki, M. Heterocyclic compound and use thereof. *EP2151440 (2010)*.
4. Kypreos, E. K. Therapy for apolipoprotein-induced hypertriglyceridemia. *WO2010020822 (2010)*.
5. Zhang, Y., Okada, Y., Tateishi, K. Deficiency in the histone demethylase JHDM2A results in impaired energy expenditure and obesity. *WO2010008463 (2010)*.
6. Bilgic, M. Solubility and stability enhancing pharmaceutical formulation. *WO2010021609 (2010)*.
7. Tendolkar, A., Palani, A., Huang, X., Aslanian, R. G. Acetylsalicylic acid derivatives useful to treat metabolic syndromes. *WO2010009210 (2010)*.
8. Tendolkar, A., Palani, A., Huang, X., Aslanian, R. G. Niacin derivatives useful to treat metabolic syndromes. *WO2010009212 (2010)*.
9. Xu, A., Wang, Y., Lam, K. S. L. Use of lipocalin-2 as a diagnostic marker and therapeutic target. *US7645616 (2010)*.

HDL CHOLESTEROL & FIBRATES

1. Clish, C., Verma, S., Forsyth, S., Souza, A., Finkel, N., Dimitrov, T., White, D. Romazarit for treating metabolic diseases. *WO2010014771 (2010)*.
2. Cooke, A.J., Bennett, D.J., Edwards, A.S., Roughton, A.L., Neagu, I., Chan, J.-H., Ho, K.-K., Ansari, N., Morris, M.L., Rong, Y., Ohlmeyer, M. 1-(4-ureidobenzoyl) piperazine derivatives. *WO2010025179 (2010)*.

INSULIN RESISTANCE & INSULIN SIGNALING

1. Hotamisligil, G. S., Özcan, U. Reducing er stress in the treatment of obesity and diabetes. *US20100075894 (2010)*.
2. Itoh, F. GSK-3beta inhibitor. *US20100069381 (2010)*.
3. Famulok, M., Hafner, M., Schmitz, A., Fuss, B., Zinke, I., Hoch, M. Use of cytohesin inhibitors for chemically inducing longevity. *US20100048594 (2010)*.

INSULIN RESISTANCE & TYPE 2 DIABETES

1. Bookser, B. C., Dang, Q., Gibson, T. S., Jiang, H., Chung, De M., Bao, J., Jiang, J., Kassick, A., Kekec, A., Lan, P., Lu, H., Makara, G. M., Romero, F. A., Sebhat, I., Wilson, D., Wodka, D. Novel cyclic

- benzimidazole derivatives useful anti-diabetic agents. **WO2010036613 (2010)**.
2. Dobak, III, J. D. Neural stimulation for treatment of metabolic syndrome and type 2 diabetes. **US7689277 (2010)**.
 3. Boatman, P. D., Johnson, B. R., Jung, J.-K., Kasem, M., Schrader, T. O., Skinner, P. J., Colletti, S. L. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders. **WO2010030360 (2010)**.
 4. Richardson, P., Baughman, R. A., Potocka, E., Boss, A. H., Petrucci, R., Howard, C., Mann, A. Use of ultrarapid acting insulin. **WO2010021879 (2010)**.
 5. Arbit, E., Dinh, S., Goldberg, M. Antidiabetic oral insulin-biguanide combination. **US20100048454 (2010)**.